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Abstract
The 1995 to 1997 lifetime carcinogenicity studies of insulin glargine in rats and mice were reanalyzed and reassessed for their
validity according to current guidelines. In 2-year studies, 50 animals per sex and per group were used. Survival rates between
weeks 80 and 90 in femalemice and rats weregreater than20 animals in all groups, fulfilling current Foodand Drug Administration
requirements that enough animals lived long enough to provide adequate exposure to glargine and to be at risk of forming late-
developing tumors. Exposure to 5 or 12.5 IU/kg glargine was similar to or 2 to 3 times greater than 5 IU/kg neutral protamine
Hagedorn insulin, respectively. Using statistical methods recommended by current guidelines, no significant effect of glargine on
mammary gland neoplastic lesions in female rodents was found, confirming earlier results. Thus, both studies can be considered
valid according to contemporary standards. Insulin glargine does not present a carcinogenic risk.
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Sequence or secondary structural modifications were intro-
duced into insulin analogues to alter their time–action profile.
1
Insulin glargine ([Gly
A21,A r g
B30,A r g
B31] insulin) is a long-
acting insulin that differs from human insulin by substitution of
asparagine by glycine in position 21 of the A-chain and by
carboxy-terminal extension of the B-chain by 2 arginine resi-
dues. These alterations shift the isoelectric point from pH 5.4 to
6.7. Because of its low solubility at physiological pH, the ana-
logue precipitates at the injection site and its subsequent slow
dissolution is the basis for its long-acting profile.
However, structural modifications of insulin may also
change its metabolic or mitogenic responses. The long-acting
analogue, insulin detemir, which has myristic acid attached to
lysine at position 29 of the B-chain, induced a modest prolif-
erative effect in the mammary gland of young female rats
during a 26-week toxicity study.
2 Clinical development of
[Asp
B10] insulin was stopped due to a higher incidence of
mammary tumors in rats in a 12-month toxicity study.
3 Com-
pared to regular human insulin, [Asp
B10] insulin displays
higher affinity toward both the insulin receptor (IR) and the
insulin-like growth factor 1 receptor (IGF-1R) in vitro, a pro-
longed occupancy time at the IR, and a higher proliferation rate
in mammalian cell lines.
4–7 Together, these results have led to
the generally held belief that insulin analogs with increased
IGF-1R affinity in vitro have increased growth-promoting
activity in vivo.
Insulin glargine has an in vitro IR signaling and metabolic
profile comparable to that of human insulin while displaying
slightly greater affinity toward IGF-1R.
4,5,7 Glargine under-
goes rapid and significant metabolism in humans and ani-
mals
8,9 leading to the formation of 2 main metabolites
[Gly
A21] human insulin (M1) and [Gly
A21, des-Thr
B30]-human
insulin (M2); these have in vitro metabolic and mitogenic
profiles comparable with human insulin.
7 Glargine was
extensively studied in 1995 to 1997 in lifetime carcinogenicity
studies in rats and mice, targeting the incidence of sponta-
neously occurring tumors and development of rare tumors.
10
There were no neoplastic findings to indicate that insulin glar-
gine had a systemic carcinogenic potential in rodents. More
recently, the validity of the studies has been questioned due
to the high mortality and lack of adequate exposure during the
study.
11,12
The lifetime carcinogenicity studies were carried out in
compliance with the testing guidelines that were in effect at
the time when the studies were conducted, that is, 1995 to 1997
(European Community Note for Guidance of October 1983
[Council recommendation, EE83/571], Ministry of Health and
Welfare Japan, September 11, 1989, and the USA Federal Reg-
ulation 50, March 4, 1985). Overall, these guidelines described
on a very general level the standards of the study design of
lifetime carcinogenicity studies.
In the meantime, a Food and Drug Administration (FDA)
guidance
13 is available which allows for approaches to high
dose selection based on toxicity end points, pharmacokinetic
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pharmacodynamic end points, and maximal feasible dose. It
specifies in detail the standards regarding statistical aspects
of the design and analysis and interpretation of chronic rodent
carcinogenicity studies of pharmaceuticals; standards are given
for the appropriate statistical analysis of tumor rates and for the
adjustment of tumor rates for intercurrent mortality. For exam-
ple, details are given for the appropriate survival rates: ‘‘As a
rule of thumb, a 50% survival rate of the 50 initial animals in
any treatment group between weeks 80 and 90 of a 2-year study
would be considered to yield a sufficient number of animals
with adequate exposure. The percentage can be lower or higher
if the number of animals used in each treatment/sex group is
larger or smaller than 50, but between 20 and 30 animals should
be still alive during these weeks.’’
The aim of the current report was to reassess the 1995 to
1997 studies for their validity with regard to design, survival
rates, incidence of neoplastic mammary lesions in female ani-
mals, statistics, and toxicokinetics according to contemporary
standards.
Methods
Study Design
The design and conduct of the 2-year studies have been fully
described, including the selection of doses, by Stammberger
et al.
10 A total of 50 animals per sex and per group were used.
Three dose levels of insulin glargine were used (2, 5, and 12.5
IU/kg) along with saline control, vehicle control, and neutral
protamine Hagedorn (NPH) insulin (12.5 in mice or 5 IU/kg in
rats) groups. The expected in-life parameters (body weight,
food consumption, survival, and behavior) were regularly mon-
itored. Animals were palpated for nodules monthly until 6
months of age and then every 2 weeks to study end. Rats found
dead were autopsied the same day.
Toxicokinetic Analyses
Blood samples for the determination of insulin were collected
from the retrobulbar venous plexus from 3 female, nonstarved
rats each at 1, 2, 3, 4, 7, and 24 hours after dose 27, 188, and
370. The vehicle control group served as the control group for
both the insulin glargine and NPH insulin groups. The blood
was centrifuged and the serum concentration of insulin was
determined by radioimmunoassay using a commercial human
insulin RIA kit (RIA-gnost Insulin; Behringwerke, Marburg,
Germany). For the insulin glargine-treated groups, a total of
100 mL of standard/sample was incubated with 200 mLo f
125I-insulin tracer and 200 mL of anti-insulin serum for 21 to
23 hours at room temperature. Antibody-bound and free radi-
olabeled ligand were separated by adding 1 mL of a 17.5%
polyethylene glycol solution to each tube and vortexing until
a homogenous solution was achieved. After centrifugation at
*1500g for 15 minutes at room temperature, the supernatant
was decanted and radioactivity in the precipitate counted. An
insulin glargine standard curve was prepared by serial dilutions
of a stock solution in human insulin-free serum. The limit of
quantification (LOQ) was 0.5 ng/mL and the measuring range
was 0.5 to 100 ng/mL. Samples >50 ng/mL were diluted. The
serum concentration of insulin in the NPH insulin-treated and
vehicle control groups was determined using the commercial
human insulin RIA kit (RIA-gnost Insulin; Behringwerke) as
described by the manufacturer. The LOQ was 7.5 mIU/mL.
Samples >165 mIU/mL were diluted. A total of 16.8 mIU/mL
corresponded to 1 ng/mL of human insulin.
Statistical Analyses
For toxicokinetic analysis, the maximum concentration (Cmax)
of insulin glargine was obtained directly from measured data.
Area under the serum insulin glargine concentration–time
curve (area under the curve [AUC]0-24 h) was calculated using
the linear trapezoidal rule where values below the LOQ were
entered as0.25 ng/mL.The 2pharmacokinetic parameters were
summarized using descriptive statistics.
For each type of tumor, statistical analyses were performed
using a modified Peto lifetime-adjusted analysis
14 and the
Bieler-Williams Poly-3 test,
15,16 2 of the recommended meth-
ods.
13 In the modified Peto lifetime adjustment, time strata
were defined, in weeks, as 0 to 50, 51 to 80, 81 to terminal
sacrifice, and terminal sacrifice. When less than 20 findings
were present, exact permutation tests were used.
17 Three sep-
arate tests were performed, a 1-tailed test for increasing mono-
tonic trend in tumor rate for the saline control group versus the
treated groups, a 1-tailed test for increasing monotonic trend in
tumor rate for the vehicle control group 2 versus the treated
groups, and a 1-tailed test for increasing monotonic trend in
tumor rate for the pooled control groups versus the treated
groups. A test for differences between the control groups was
also performed at the 5% level. Pairwise comparisons between
the controls (separately or pooled) and the high-dose group
were performed.
A Bieler-Williams Poly-3 test approach does not depend on
the classification of tumors (fatal or incidental). It is a survival-
adjusted quantal-response procedure that modifies the denomi-
nator in the quantal estimate of lesion incidence of the
Cochran-Armitage linear trend test to approximate more
closely the total number of animal-years at risk. The thresholds
considered were those given in the FDA guidance
13 for trend
tests; 0.025 for rare tumors and 0.005 for common tumors and,
for control-high pairwise comparisons, 0.05 for rare tumors and
0.01 for common tumors. All tumor analyses were performed
using the MULTTEST and LIFETEST procedures in version
9.1 of the SAS system on Windows XP.
Results
Study Design
The current guidelines call for 2-year carcinogenicity studies in
rats and mice with 50 animals per sex and per group, 3 dose
138 International Journal of Toxicology 31(2)levels of experimental drug plus saline and vehicle control
groups and, if appropriate, a comparator group. The design and
conduct of both studies meet the practice guidelines of the
present time.
Survival Rates
More than 20 female mice were still alive at week 80 in all
groups but not at week 90 (Table 1). In the saline control group,
23 mice were alive at the start of week 86; in the vehicle control
group, 20 were alive at the start of week 87; in the glargine low-
dose group, 21 were alive at the start of week 84, while 21
animals remained at week 90 in the middle-dose group and 27
in the high-dose group. There were 21 animals alive at week 90
in the NPH group.
For female rats, more than 20 animals were still alive at
week 80 in all groups and at week 90 in all but the high-dose
group (Table 1). Only in the high-dose groupthe number of live
animals was below 20 at week 90; and in this group, 21 animals
were still alive at the start of week 89. Thus, comparing these
survival rates with the FDA ‘‘rule of thumb’’ that 20 to 30
animals should still be alive between weeks 80 and 90, it is
considered that there were enough animals living long enough
to provide adequate exposure to the drug and to be at risk of
forming late-developing tumors in both studies.
Statistical Analyses
Malignant tumors were found in mammary glands from 2
female mice in the saline control group and in 2 from the
glargine high-dose group. Analysis of tumor incidence
revealed no statistical significant difference between the con-
trol groups and the glargine high-dose group using either the
Peto analysis at the 5% level (Table 2) or the Bieler-Williams
Poly-3 test at the 2.5% level. In the latter analysis, P values for
treated versus saline control, vehicle control, or dual control
groups were 0.5934, 0.0334, and 0.3738, respectively. Similar
results were obtained with rats using either the Peto analysis of
individual tumor (Table 2) or combined tumor (Table 3) inci-
dences, or using the Bieler-Williams Poly-3 test (Table 4). Raw
mammary tumor data are available in Supplemental Tables 1
and 2.
Exposure to Drug
The toxicokinetic parameters of insulin glargine in female rats
are summarized in Table 5. Both Cmax and AUC0-24 h increased
Table 1. Survival Rates in Female Mice and Female Rats From Weeks 80 to 90 and at Scheduled Termination (Weeks 105-107)
Survival Rates in Female Mice, n (%)
Week SC VC GLA 2 GLA 5 GLA 12.5 NPH 12.5
Week 0 50 (100) 50 (100) 50 (100) 50 (100) 50 (100) 50 (100)
Week 80 32 (64) 26 (52) 25 (50) 31 (62) 36 (72) 28 (56)
Week 81 32 (64) 25 (50) 25 (50) 31 (62) 36 (72) 28 (56)
Week 82 28 (56) 25 (50) 22 (44) 30 (60) 35 (70) 28 (56)
Week 83 27 (54) 24 (48) 21 (42) 27 (54) 34 (68) 27 (54)
Week 84 26 (52) 23 (46) 21 (42) 26 (52) 32 (64) 26 (52)
Week 85 25 (50) 23 (46) 19 (38) 24 (48) 30 (60) 25 (50)
Week 86 23 (46) 22 (44) 18 (36) 24 (48) 29 (58) 24 (48)
Week 87 19 (38) 20 (40) 18 (36) 24 (48) 28 (56) 23 (46)
Week 88 19 (38) 19 (38) 17 (34) 24 (48) 28 (56) 22 (44)
Week 89 17 (34) 17 (34) 16 (32) 21 (42) 28 (56) 22 (44)
Week 90 16 (32) 17 (34) 15 (30) 21 (42) 27 (54) 21 (42)
Terminal sacrifice 3 (6) 5 (10) 5 (10) 9 (18) 11 (22) 11 (22)
Survival rates in female rats, n (%)
Week SC VC GLA 2 GLA 5 GLA 12.5 NPH 5
Week 0 50 (100) 50 (100) 50 (100) 50 (100) 50 (100) 50 (100)
Week 80 35 (70) 37 (74) 36 (72) 37 (74) 30 (60) 36 (72)
Week 81 35 (70) 37 (74) 36 (72) 37 (74) 29 (58) 36 (72)
Week 82 35 (70) 37 (74) 35 (70) 37 (74) 27 (54) 36 (72)
Week 83 34 (68) 36 (72) 33 (66) 36 (72) 26 (52) 35 (70)
Week 84 34 (68) 36 (72) 33 (66) 34 (68) 26 (52) 35 (70)
Week 85 34 (68) 35 (70) 32 (64) 34 (68) 24 (48) 34 (68)
Week 86 33 (66) 34 (68) 31 (62) 33 (66) 23 (46) 34 (68)
Week 87 31 (62) 32 (64) 29 (58) 33 (66) 23 (46) 34 (68)
Week 88 30 (60) 32 (64) 29 (58) 30 (60) 22 (44) 33 (66)
Week 89 30 (60) 32 (64) 28 (56) 30 (60) 21 (42) 33 (66)
Week 90 30 (60) 30 (60) 28 (56) 30 (60) 18 (36) 33 (66)
Terminal sacrifice 21 (42) 19 (38) 18 (36) 16 (32) 7 (14) 9 (18)
Abbreviations: GLA, insulin glargine; SC, saline control; VC, vehicle control.
Stammberger and Essermeant 139with repeated dosing and with increasing dosing for insulin
glargine and with repeated dosing for the single dose of NPH
insulin.Meanvalues of both CmaxandAUC0-24 h at 5 U/kg insulin
glargine were similar to or greater than those with 5 U/kg NPH
insulin and were approximately 2- to 3-fold greater at 12.5 U/kg
insulin glargine compared with 5 U/kg NPH insulin.
Table 2. Female Mice and Rats—Mammary Gland Tumor Incidence Peto Analysis
Tumor Group SC
a VC
a GLA 2 GLA 5 GLA 12.5
b
Mice
Adenocarcinoma Examined tissues 38 41 46 45 46
Nonlethal tumors 0 0 0 0 1
Lethal tumors 2 0 0 0 1
Treated versus Dual 0.4891 0.5157
Treated versus SC 0.6932 0.7290
Treated versus VC 0.0790 0.0790
Rats
Adenocarcinoma Examined tissues 50 47 49 49 49
Nonlethal tumors 6 8 6 7 5
Lethal tumors 3 1 1 1 2
Treated versus Dual 0.7826 0.8189
Treated versus SC 0.6579 0.7127
Treated versus VC 0.7442 0.7912
Adenoma Lethal tumors 0 1 3 0 0
Treated versus Dual 0.8174 0.6315
Treated versus SC 0.8629 0.6718
Treated versus VC 0.9310 0.8275
Carcinoma arising in fibroadenoma Nonlethal tumors 1 2 1 1 1
Lethal tumors 2 0 0 0 1
Treated versus Dual 0.5224 0.5654
Treated versus SC 0.5787 0.6292
Treated versus VC 0.3548 0.3914
Fibroadenoma Nonlethal tumors 21 20 22 18 15
Lethal tumors 5 1 4 4 0
Treated versus Dual 0.8679 0.8304
Treated versus SC 0.9577 0.9428
Treated versus VC 0.7422 0.6738
Mixed tumor malignant Lethal tumors 0 2 0 0 0
Treated versus Dual 1.000 1.000
Treated versus SC 1.000 1.000
Treated versus VC 1.000 1.000
Abbreviations: Dual, SC plus VC; GLA, insulin glargine; SC, saline control; VC, vehicle control.
a P values from upper-tailed Peto trend tests.
b P values from upper-tailed Peto pairwise comparisons to the control.
Table 3. Female Rats—Mammary Gland Combined Tumor Incidence Peto Analysis
Tumor Group SC
a VC
a GLA 2 GLA 5 GLA 12.5
b
Benign combined Examined tissues 50 47 49 49 49
Nonlethal tumors 21 20 22 18 15
Lethal tumors 5 1 4 4 0
Treated versus Dual 0.8679 0.8304
Treated versus SC 0.9577 0.9428
Treated versus VC 0.7422 0.6738
Malignant combined Nonlethal tumors 7 8 7 8 6
Lethal tumors 5 3 1 1 3
Treated versus Dual 0.7623 0.7988
Treated versus SC 0.6684 0.7209
Treated versus VC 0.6448 0.6931
Abbreviations: Dual, SC plus VC; GLA, insulin glargine; SC, saline control; VC, vehicle control.
a P values from upper-tailed Peto trend tests.
b P values from upper-tailed Peto pairwise comparisons to the control.
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In 2-year studies conducted in 1995 to 1997, insulin glargine
was shown to not have carcinogenic potential in mice or
rats.
3 The validity of those studies, however, has been ques-
tioned based on the high rate of mortality and presumed
lack of adequate drug exposure.
11,12 Because revised guide-
lines have been published since the studies were completed,
the design of the studies, the survival rates, and the inci-
dence of neoplastic mammary lesions in female animals
were reassessed for their validity according to current
guidelines. The design of these studies and the survival rates
in both the mouse and rat carcinogenicity studies were
f o u n dt ob ea d e q u a t et oa s s e s st he carcinogenic potential
of insulin glargine; there were sufficient numbers of animals
who lived long enough to provide adequate exposure to the
drug and to be at risk of forming late-developing tumors.
Using methods recommended by the current guidelines, no
statistically significant effect of glargine on mammary gland
neoplastic lesions in either female mice or rats was found,
confirming the earlier results.
10 Thus, both studies can be
considered valid according to modern-day standards.
The lowest dose of insulin glargine used in the carcino-
genicity studies (2 IU/kg) is approximately 2 to 4 times the
mean daily human dose (0.5-1.0 IU/kg).
18,19 The highest
dose of glargine (12.5 IU/kg) was found to be the maximum
tolerated dose for a lifetime study.
10 Rats injected with the
supraphysiological dose of 5 IU/kg insulin glargine resulted
in similar exposure over time, as measured by Cmax and
AUC0-24 h, as the same dose of NPH insulin, while the
highest dose of insulin glargine resulted in exposure that
was 2 to 3 times greater over time than 5 IU/kg NPH insu-
lin. These results supported the conclusion that there was
adequate exposure in the carcinogenicity studies for the
animals to be at risk of developing late-forming tumors. Yet
t h er i s kw a sf o u n dt ob en og r eater for animals treated with
insulin glargine than for the control-treated animals. Insulin
glargine remains the only insulin analog that has undergone
such extensive toxicological and carcinogenicity testing.
20
In conclusion, the present reassessment of the 2-year
insulin glargine carcinogenicity studies confirms the earlier
findings that this basal insulin analog does not present a
carcinogenic risk. Together with a metabolic and mitogenic
profile in vitro that is similar to human insulin, these results
indicate that insulin glargine is not likely to pose a cancer
risk in humans. These findings may be confirmed by
ongoing clinical studies.
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